斑塊性乾癬、乾癬性關節炎、僵直性脊椎炎、化膿性汗腺炎<20231219>
Plaque psoriasis (candidates for systemic therapy or phototherapy); Psoriatic arthritis; Ankylosing spondylitis

Anti-interleukin 17A Monoclonal Antibody
Secukinumab selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines.

Absorption:
Bioavailability: 55% to 77%
Distribution:
Vd: 7.1 to 8.6 L
Metabolism:
Expected to be degraded into small peptides and amino acids via catabolic pathways similar to that which is seen with endogenous IgG
Pharmacodynamics:
1. Half-life elimination: 22 to 31 days
2. Time to peak: ~6 days

Serious hypersensitivity reaction to secukinumab or any component of the formulation

Adverse events were not observed in animal reproduction studies.
Other agents are currently preferred for the treatment of plaque psoriasis in pregnant women.

It is not known if secukinumab is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk and benefits.

>10%: Infection, hypersensitivity, Nasopharyngitis
<10%: Headache, Urticaria, candidiasis, Hypercholesterolemia,Diarrhea, nausea, inflammatory bowel disease, oral herpes, herpes virus infection, staphylococcal infection, upper respiratory tract infection, pharyngitis, rhinitis, rhinorrhea

Administration: SUBQ
Dosage:
Ankylosing spondylitis
1. With a loading dose: 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks; consider an increase to 300 mg every 4 weeks in patients who continue to have active ankylosing spondylitis.
2. Without a loading dose: 150 mg every 4 weeks; consider an increase to 300 mg every 4 weeks in patients who continue to have active ankylosing spondylitis/psoriatic arthritis.
3. Coexistent moderate to severe plaque psoriasis: 300 mg once weekly at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Some patients may only require 150 mg per dose.
Axial spondyloarthritis (nonradiographic)
1. With a loading dose: 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks.
2. Without a loading dose: 150 mg every 4 weeks.
Plaque psoriasis:
300 mg once weekly at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Some patients may only require 150 mg per dose.
Hidradenitis suppurativa:
300 mg at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks; consider an increase to 300 mg every 2 weeks in patients who have an inadequate response. <20231219>

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).